MS Brain Changes: What Shrinking Grey Matter Means Now

Credibility

Interest

Share:2 min read

Key Takeaway

People with relapsing-remitting MS show faster loss of brain grey matter in specific frontal regions and the thalamus, similar to about 20 years of normal ageing.

What They Found

Researchers followed people with relapsing-remitting MS for up to 12 years and looked at changes in grey matter, the brain tissue important for thinking and movement. The biggest and most consistent shrinking was found in parts of the frontal lobes (areas that help with planning, decision making, and controlling behavior) and in the thalamus (a deep brain area that routes signals). When compared to healthy people, the MS group had grey matter loss like that seen in people about 20 years older, especially in right-side frontal regions and some deep brain structures. Only one clinical measure of disability (EDSS, a scale doctors use to rate physical disability) matched the brain changes consistently, and that was linked to shrinkage in the left hippocampus (a memory-related area). The study used two separate groups of MS patients and a large group of healthy people, so the main regional patterns were found more than once, making the results more reliable.

Who Should Care and Why

People with relapsing-remitting MS should care because the study shows certain brain areas can shrink faster than normal ageing, which may explain some symptoms like thinking problems or movement changes. Caregivers can use this idea like watching a car part that wears out faster — knowing which parts are most at risk helps plan maintenance, therapy, or monitoring. Doctors and therapists can use these findings to focus on treatments and tests that track frontal lobe and thalamus health, for example by asking about planning, attention, or movement changes. Patients who notice worsening memory, thinking speed, or coordination might mention these specific concerns to their care team so imaging or rehab can be considered. The findings help target which symptoms may be most connected to brain changes and suggest where monitoring and support could be most useful.

Important Considerations

The study shows associations but does not prove that the brain changes cause specific symptoms, so results are a guide not a diagnosis. The link between brain shrinkage and clinical problems was strongest for one disability measure and not consistent across all tests, so individual experiences may differ. Also, most comparisons are statistical averages; not every person with MS will have the exact pattern or speed of change seen in the study.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Progression MS Diagnostics Early Research

Article Topics:

Frontal LobeGrey MatterMRIMultiple SclerosisThalamusVolume Loss

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like NeuroImage often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News